An observational study in Sacroiliac Joint Dysfunction, Multifidus and Pain Management, sponsored by Fatih Sultan Mehmet Training and Research Hospital. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Fatih Sultan Mehmet Training and Research Hospital · Observational
This retrospective comparative cohort study aims to compare the short-term clinical outcomes of ultrasound-guided sacroiliac joint (SIJ) injection, combined SIJ and multifidus injection, and multifidus injection alone in patients with sacroiliac joint dysfunction. Medical records of patients who underwent ultrasound-guided injection procedures were retrospectively reviewed and classified into three groups according to the documented injection target: SIJ injection alone, combined SIJ and multifidus injection, and multifidus injection alone. The primary outcome is the change in pain intensity during movement, assessed using the Visual Analog Scale (VAS) from baseline to 30 minutes after injection. Pain outcomes at one week and changes in functional measures, including the Roland-Morris Disability Questionnaire and Oswestry Disability Index, are evaluated as secondary outcomes. The study aims to determine whether short-term pain and functional outcomes differ according to the injection target.
1,269 studies on the registry are indexed under Agnosia; 524 are open to participants now.
This study's planned enrollment of 30 is below the median of 119 across 158 observational studies indexed under Agnosia.
Browse Agnosia studies →Fatih Sultan Mehmet Training and Research Hospital is the lead sponsor of 120 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consisted of adult patients with chronic low back pain and sacroiliac joint dysfunction who were evaluated at the Physical Medicine and Rehabilitation outpatient clinic between January 1, 2023, and August 15, 2025. Medical records of patients who underwent ultrasound-guided sacroiliac joint and/or multifidus injection as part of routine clinical care were retrospectively reviewed. Eligible patients were classified into three cohorts according to the injection target documented in their medical records: sacroiliac joint injection alone, combined sacroiliac joint and multifidus injection, or multifidus injection alone. No treatment was assigned for research purposes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with sacroiliac joint dysfunction who received ultrasound-guided intra-articular sacroiliac joint injection alone as part of routine clinical care. A total of 2.0 mL of 2% lidocaine was administered into the sacroiliac joint.
Procedure: Ultrasound-Guided Sacroiliac Joint Injection
Patients with sacroiliac joint dysfunction who received ultrasound-guided intra-articular sacroiliac joint injection followed by an intramuscular multifidus injection as part of routine clinical care. A total of 2.0 mL of 2% lidocaine was administered to the sacroiliac joint and 2.0 mL of 2% lidocaine was administered to the multifidus muscle.
Procedure: Ultrasound-Guided Sacroiliac Joint Injection · Procedure: Ultrasound-Guided Multifidus Injection
Patients with sacroiliac joint dysfunction who received ultrasound-guided intramuscular multifidus injection alone as part of routine clinical care, without entering the sacroiliac joint. A total of 2.0 mL of 2% lidocaine was administered to the multifidus muscle.
Procedure: Ultrasound-Guided Multifidus Injection
Ultrasound-guided intra-articular sacroiliac joint injection was performed with the patient in the prone position. The sacroiliac joint and surrounding vascular structures were identified using ultrasonography and color Doppler imaging. A 22-gauge, 3.5-inch spinal needle was advanced toward the sacroiliac joint under ultrasound guidance. After confirming the absence of intravascular placement, 2.0 mL of 2% lidocaine was administered intra-articularly.
Ultrasound-guided intramuscular multifidus injection was performed with the patient in the prone position. After ultrasonographic identification of the relevant sacral anatomical landmarks and the multifidus muscle, a 22-gauge, 3.5-inch spinal needle was advanced into the multifidus muscle under ultrasound guidance. After confirming the absence of intravascular placement, 2.0 mL of 2% lidocaine was administered intramuscularly.
Change in Pain Intensity During Movement Assessed Using the Visual Analog Scale (VAS)
Pain intensity during movement was assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, with 0 indicating no pain and 10 indicating the worst imaginable pain. Higher scores indicate greater pain intensity and therefore a worse outcome. Changes in Visual Analog Scale scores were evaluated from baseline to 30 minutes and 1 week after the injection.
Time frame: Baseline, 30 minutes after injection, and 1 week after injection
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Oct 2026, 0 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fatih Sultan Mehmet Training and Research Hospital →